This data was validated in immune competent RPM lung tumors, and it was observed that FOXM1 inhibitors alone (FDI-6/NB-73) or in combination with cisplatin (FDI-6) enhanced infiltration of CD8 + cytotoxic T cells in the tumor microenvironment (Fig. 6G–H, supplementary Fig. S20A). The gene discussed is CD8A; the disease is neoplasm.